Compare ASAN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASAN | VCEL |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2020 | 1996 |
| Metric | ASAN | VCEL |
|---|---|---|
| Price | $7.88 | $34.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $12.46 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 6.8M | 588.1K |
| Earning Date | 06-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.93 | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $790,806,000.00 | $276,259,000.00 |
| Revenue This Year | $10.19 | $19.40 |
| Revenue Next Year | $7.91 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.25 | ★ 16.45 |
| 52 Week Low | $5.38 | $28.95 |
| 52 Week High | $15.71 | $45.97 |
| Indicator | ASAN | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 57.22 |
| Support Level | $7.15 | $35.85 |
| Resistance Level | $8.20 | $37.68 |
| Average True Range (ATR) | 0.51 | 1.56 |
| MACD | 0.22 | 0.05 |
| Stochastic Oscillator | 59.73 | 88.48 |
Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.